Vanguard Group Inc. Purchases 64,367 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Vanguard Group Inc. increased its stake in Arcturus Therapeutics by 3.8%, now owning 1,748,928 shares valued at approximately $18.5 million.
• The stock price of Arcturus Therapeutics has recently seen fluctuations, currently at $17.01, with a 52-week range between $8.04 and $25.88.
• Analysts maintain a generally positive outlook on the stock, with an average rating of "Buy" and a target price of $50.57, despite some revisions downwards on price targets from various firms.

Vanguard Group Inc. increased its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,748,928 shares of the biotechnology company's stock after purchasing an additional 64,367 shares during the quarter. Vanguard Group Inc. owned 6.45% of Arcturus Therapeutics worth $18,521,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Byrne Asset Management LLC boosted its position in shares of Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 1,365 shares during the period. US Bancorp DE lifted its stake in Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after buying an additional 2,329 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Arcturus Therapeutics by 3,482.9% in the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after buying an additional 5,085 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth approximately $200,000. Finally, Brevan Howard Capital Management LP raised its holdings in shares of Arcturus Therapeutics by 13.7% during the fourth quarter. Brevan Howard Capital Management LP now owns 12,305 shares of the biotechnology company's stock valued at $209,000 after acquiring an additional 1,486 shares during the period. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ARCT shares. Citigroup reiterated a "buy" rating and set a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Wells Fargo & Company lowered their target price on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. Finally, Leerink Partners lowered their price objective on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research report on Friday, August 22nd. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $50.57.

Arcturus Therapeutics Stock Up 2.8%

Shares of NASDAQ:ARCT traded up $0.47 on Wednesday, reaching $17.17. The company had a trading volume of 203,240 shares, compared to its average volume of 471,025. The stock has a market capitalization of $466.34 million, a P/E ratio of -7.68 and a beta of 2.39. The stock has a 50-day moving average price of $14.73 and a 200 day moving average price of $13.37. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.77. The business had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.